PathAI expands AISight Clinical Trials Platform
PathAI announced the strategic expansion of its support of inflammatory bowel disease clinical trials on the AISight Clinical Trials Platform with the launch of IBDExplore to join AIM-HI UC.
The AISight Clinical Trials Platform provides a robust, GCP/GCLP-compliant environment that bridges the gap between traditional pathology and computational precision. By launching these tools on AISight Clinical Trials, PathAI enables biopharma partners to:
- Deploy AI-powered Endpoints: Easily integrate AI-driven histology scores into existing trial workflows to strengthen clinical data packages.
- Hybrid Workflow Support: The platform uniquely supports both manual histology reads and AI-powered computational reads in a single, unified interface.
- Seamless Data Flow: Automated outputs are designed to be trial-ready, providing the scalability needed for global, multi-site studies.
While AIM-HI UC provides standardized, reproducible histologic scoring, IBDExplore transforms standard H&E-stained histology whole slide images into rich maps of scalable, quantitative spatial insights. When integrated into clinical trial outputs as an exploratory endpoint, IBDExplore empowers researchers to:
- Uncover Mechanism of Action (MoA): Analyze cellular relationships and tissue architecture changes in response to therapy.
- Differentiate in the Market: Identify subtle nuances of response that traditional scoring might miss, providing a competitive edge in therapy positioning.
IBDExplore, AIM-HI UC, and AISight Clinical Trials Platform are For Research Use Only. Not for use in diagnostic procedures.
